DAWN - Day One Biopharma reaches session low as post IPO momentum loses steam

Despite a ~61.8% gain on public debut, Day One Biopharmaceuticals ([[DAWN]] -17.3%) is one course to record a sharp one-day loss after reaching a session low today.The company remained ~38.6% higher through yesterday after pricing the IPO at $16.00 apiece at the top of an expected $14.00 - to $16.00-a-share range.With the offer of 10M common shares, the company anticipated $160M in gross proceeds. Underwriters have an option to purchase an additional 1.5M shares.Day One Biopharmaceuticals was among a trio of companies to make strong trading debuts on Thursday.The healthcare-apparel maker Figs and Singular Genomics focused on the human genome rose ~44.6% and ~16.9% on their first day of trading, respectively. However, the latter has extended recent losses for the third straight session today.

For further details see:

Day One Biopharma reaches session low as post IPO momentum loses steam